Drug Trial Radar · NCT02799706
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
885
Planned (sponsor's estimate)
Start
Sep 25, 2017
Primary completion
Aug 23, 2023
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Jun 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH agonists in combination with external beam radiation therapy. Secondary objectives include: * documentation of effect of GnRH antagonists on clinically significant cardiovascular events in the subgroup of patients at high risk of such events at baseline; * documentation of side effects and quality of life, I-PSS and urinary tract infections; * assessment of relative treatment effect on secondary efficacy endpoints (clinical progression, time to next line of systemic therapy, time on therapy, overall and cancer specific survival) and on PSA at 6 months after end of RT.
Conditions
- Prostate Cancer
Interventions
DegarelixDrug
a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
approved GnRH agonistDrug
A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
RadiotherapyRadiation
.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: through study completion, an average of 1 year
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet
Brussels, Belgium
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hopital De Jolimont
Haine-Saint-Paul, Belgium
AZ Groeninge Kortrijk - Campus Kennedylaan
Kortrijk, Belgium
CHU Ucl Namur - Site Sainte-Elisabeth
Namur, Belgium
Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus
Wilrijk, Belgium
University Hospitals Copenhagen - Rigshospitalet
Copenhagen, Denmark
Clinique de l'Europe
Amiens, France
Centre de radiotherapie Marie Curie
Arras, France
Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque
Bayonne, France
Groupe Radiopole Artois - Centre de Radiotherapie Pierre Curie
Beuvry, France
CHU de Grenoble - La Tronche - Hôpital A. Michallon
Grenoble, France
Centre Leon Berard
Lyon, France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Nantes, France
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
Paris, France
Centre Hospitalier Privé Saint-Grégoire
Saint-Grégoire, France
Clinique Pasteur-Toulouse-Atrium
Toulouse, France
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Otto-Von-Guericke-Universitaet Magdeburg - Universitaetsklinik
Magdeburg, Germany
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
AUSL Romagna - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
Fundacion Hospital Alcorcon
Alcorcón, Spain
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
Barcelona, Spain
Clinica IMQ Zorrotzaurre
Bilbao, Spain
Hospital General Universitario Santa Lucia
Cartagena, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitario de Gran Canaria Doctor Negrin
Las Palmas de Gran Canaria, Spain
Complejo Hospitalario A
Pamplona, Spain
Corporacio Sanitaria Parc Tauli
Sabadell, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Consorci Sanitari De Terrassa
Terrassa, Spain
Complejo Hospitalario Universitario de Vigo -CHUVI - Hospital Alvaro Cunqueiro
Vigo, Spain
Oncology Institute of Southern Switzerland (IOSI) - Oncology Institute of Southern Switzerland - Ospedale Regionale Bellinzona e Valli
Bellinzona, Switzerland
Inselspital
Bern, Switzerland
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie
Geneva, Switzerland
Nottingham University Hospitals NHS Trust - City Hospital
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.